1233 Impact of infections occurring in patients receiving immune checkpoint inhibitors for renal cell carcinoma (RCC)

BackgroundImmune checkpoint inhibitor (ICI)-based regimens including pembrolizumab/axitinib (P/A), nivolumab/cabozantinib (N/C), and nivolumab/ipilimumab (N/I) have improved outcomes in patients with RCC. While immune related adverse events are a well-known complication contributing to treatment del...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2023-11, Vol.11 (Suppl 1), p.A1360-A1360
Main Authors: Wiechmann, Catherine, Gee, Kelly, Burns, Ethan, Xu, Jiaqiong, Zhang, Yuqi, Crenshaw, Aubrey, Esmail, Abdullah, Kieser, Ryan, Umoru, Godsfavour, Muhsen, Ibrahim, Sun, Kai, Gong, Zimu, Shah, Shivan, Singh, Monisha, Zhang, Jun, Efstathiou, Eleni, Abdelrahim, Maen
Format: Article
Language:English
Subjects:
Immunotherapy
Infections
Kidney cancer
Regular and Young Investigator Award Abstracts
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundImmune checkpoint inhibitor (ICI)-based regimens including pembrolizumab/axitinib (P/A), nivolumab/cabozantinib (N/C), and nivolumab/ipilimumab (N/I) have improved outcomes in patients with RCC. While immune related adverse events are a well-known complication contributing to treatment delays, discontinuation, and morbidity, little is reported on the incidence and outcomes of infections. This study aims to assess the incidence, risk factors, and outcomes of infections occurring in patients with RCC receiving ICIs.MethodsData was collected from 7 hospitals for patients who received P/A, N/C, or N/I for RCC from 1/2017–8/2021. Date of last follow-up was 12/2022. Covariates compared among infected and non-infected cohorts included age, gender, race, comorbidities, and ECOG. Risk factors for infection were assessed by univariable analysis with reported odds ratio (OR) and 95% confidence interval (CI). Outcome measures included all-cause emergency department (ED) visits, inpatient, and intensive care unit (ICU) admissions, median number of ICI cycles, progression free survival (PFS) and overall survival (OS). OS/PFS were evaluated using the Kaplan-Meier model. P-value 1 (OR 6.22, [95% CI 1.92, 19.73], p=0.002) was associated with higher risk of developing infections. Infected patients had a higher rate of ED (14 (27.45%) vs 13 (13.27%), p= 0.033), inpatient (40 (78.43%) vs 42 (42.86%), p
ISSN:2051-1426
DOI:10.1136/jitc-2023-SITC2023.1233